



SymBio Pharmaceuticals Limited

San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

April 15, 2009

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director
President and Chief Executive Officer

SymBio Pharmaceuticals Limited Executes Third Party Allocation of New Shares to Mitsubishi UFJ Capital Limited Partnership Fund

TOKYO, Japan, April 15, 2009 -- SymBio Pharmaceuticals Limited (“SymBio”) today announced that third-party allocation of new shares to the Mitsubishi UFJ Capital Limited partnership fund (general partner is Mitsubishi UFJ Capital) was resolved at a board meeting held on April 14, 2009 in the company’s ongoing Series C round of fundraising. Payment was received by SymBio from Mitsubishi UFJ Capital today.

SymBio concluded a commitment line agreement of 500 million JPY with Bank of Tokyo-Mitsubishi UFJ in December 2008.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company’s underlying corporate philosophy is “delivering hope to patients in need,” and the company aims to address unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

Atsushi Kanazawa

Director, Corporate Planning & Development

Tel: +81-3-5472-1123

E-mail: Please send your inquiry through “INQUIRY” in our homepage.

URL: <http://www.symbiosis.co.jp>